According to reports from Business Standard, Vista Pharmaceuticals reported a standalone net loss of ₹0.99 crore for the quarter ended June 2026, representing a 23% improvement from the net loss of ₹1.29 crore recorded in the corresponding quarter of the previous year. The company's financial performance showed mixed results across key metrics during the quarter.
As reported by Business Standard, the company experienced a complete revenue decline with zero sales reported in the quarter ended June 2026, compared to ₹1.52 crore in sales during the same quarter of the previous year. This represents a 100% decline in revenue generation year-over-year, indicating significant operational challenges during the quarter.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) stood at 0% for the quarter ended June 2026, compared to 73.03% in the corresponding quarter of the previous year. The PBDT (Profit Before Depreciation and Tax) improved to -₹1.14 crore from -₹1.30 crore in the previous year, showing a 12% improvement in this metric.
As reported by Business Standard, the company's PBT (Profit Before Tax) improved to -₹1.33 crore in the quarter ended June 2026, compared to -₹1.48 crore in the corresponding quarter of the previous year, representing a 10% improvement in this metric. This improvement in profit before tax indicates better cost management despite the revenue challenges faced during the quarter.
